Nuvation Bio Inc. $NUVB is Aisling Capital Management LP’s 4th Largest Position

Aisling Capital Management LP lifted its position in shares of Nuvation Bio Inc. (NYSE:NUVB) by 16.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,960,659 shares of the company’s stock after acquiring an additional 419,650 shares during the quarter. Nuvation Bio accounts for about 2.4% of Aisling Capital Management LP’s holdings, making the stock its 4th biggest position. Aisling Capital Management LP owned about 0.86% of Nuvation Bio worth $10,954,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Rafferty Asset Management LLC raised its holdings in Nuvation Bio by 40.7% during the third quarter. Rafferty Asset Management LLC now owns 39,905 shares of the company’s stock worth $148,000 after purchasing an additional 11,539 shares during the last quarter. R Squared Ltd purchased a new position in shares of Nuvation Bio in the third quarter valued at $51,000. Northwest Quadrant Wealth Management LLC purchased a new position in shares of Nuvation Bio in the third quarter valued at $40,000. Palumbo Wealth Management LLC raised its stake in shares of Nuvation Bio by 17.8% during the 3rd quarter. Palumbo Wealth Management LLC now owns 133,861 shares of the company’s stock worth $495,000 after buying an additional 20,195 shares during the last quarter. Finally, AXQ Capital LP raised its stake in shares of Nuvation Bio by 23.3% during the 3rd quarter. AXQ Capital LP now owns 117,610 shares of the company’s stock worth $435,000 after buying an additional 22,215 shares during the last quarter. 61.67% of the stock is owned by hedge funds and other institutional investors.

Nuvation Bio Price Performance

NUVB stock opened at $4.37 on Wednesday. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -7.28 and a beta of 1.50. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14. Nuvation Bio Inc. has a 52-week low of $1.54 and a 52-week high of $9.75. The stock’s fifty day simple moving average is $6.55 and its 200-day simple moving average is $5.54.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). The firm had revenue of $41.87 million for the quarter, compared to the consensus estimate of $36.82 million. Nuvation Bio had a negative return on equity of 54.90% and a negative net margin of 325.31%. Equities research analysts expect that Nuvation Bio Inc. will post -0.36 EPS for the current year.

More Nuvation Bio News

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Strong commercial traction for IBTROZI: company reported 216 new patient starts in Q4 and 432 total starts since launch, and highlighted rapid adoption across treatment lines — supports revenue growth expectations and commercial momentum. PR Newswire: Q4 results & business update
• Positive Sentiment: Strategic collaboration: exclusive licensing/collaboration agreement with Eisai for taletrectinib in Europe and additional territories expands commercialization reach and derisks regional launch execution. PR Newswire: Eisai collaboration
• Positive Sentiment: Revenue beat and strong liquidity: Q4 revenue of $41.87M topped consensus (~$36.8M) and company reported $529.2M in cash, cash equivalents and marketable securities — gives runway for commercialization and R&D. Zacks: Q4 revenue beat
• Positive Sentiment: Clinical progress beyond IBTROZI: published positive Phase 2 safusidenib results showing durable responses in IDH1-mutant glioma and ongoing SIGMA protocol amendment — supports pipeline optionality. FinanzNachrichten: Q4 results & safusidenib update
• Neutral Sentiment: Earnings cadence: GAAP EPS loss of ($0.11) matched consensus (improved versus prior year loss) — meets expectations but is not an upside catalyst on its own. MarketBeat: Q4 EPS & call
• Neutral Sentiment: Management commentary & strategy: Q4 call and presentations outline first-line IBTROZI growth strategy and longer median DOR messaging — informative but will take time to convert into durable financial gains. Seeking Alpha: IBTROZI strategy
• Negative Sentiment: Analyst downgrade and target cut from UBS: UBS lowered its price target from $10 to $7 and moved to “neutral” — a direct negative signal that likely pressured the stock. Benzinga: UBS target cut
• Negative Sentiment: Profitability concerns remain: company still posts large negative net margins and negative ROE despite revenue growth — a reminder that commercial ramp must outpace costs to justify higher valuations. MarketBeat: financial metrics

Analysts Set New Price Targets

NUVB has been the topic of a number of research reports. Truist Financial set a $13.00 price objective on shares of Nuvation Bio in a research note on Tuesday, January 27th. UBS Group reduced their price target on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research note on Thursday, January 22nd. Royal Bank Of Canada lifted their price objective on Nuvation Bio from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.44.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.